LEMAITRE VASCULAR INC

LMAT represents LeMaitre Vascular, Inc., a medical device company that develops, manufactures, and markets vascular surgical devices. Its products are used in procedures such as carotid endarterectomy, peripheral vascular bypass, and hemodialysis access. The company sells primarily to hospitals and clinics in the United States and international markets. LMAT is listed on the Nasdaq Global Select Market under the ticker symbol LMAT. For a full company description and latest disclosures, refer to the LMAT stock detail page.

The latest price of LMAT stock is displayed at the top of the LMAT stock detail page and updates during regular trading hours. Because prices change continuously, any figure quoted here could quickly become outdated. For the most current quote, including intraday movement, bid/ask, and volume, please check the live data shown on the page. That information reflects the most recent market activity for LMAT.

Whether LMAT appears overvalued or undervalued depends on the valuation metrics you use and the assumptions behind them. Common approaches compare LMAT's price-to-earnings, price-to-sales, or enterprise-value multiples with those of peers and with its own historical range. Growth expectations, margins, and risk also matter. Since these inputs change over time, review the latest LMAT valuation data and financial statements on the page rather than relying on a single label.

LMAT shares trade on the Nasdaq Global Select Market under the ticker LMAT. Investors can buy or sell them through a brokerage account that offers U.S. equity trading, typically via a mobile app, website, or by phone. Orders are matched during the regular session, and some brokers also offer extended-hours trading. Availability, order types, and fees vary by broker, so confirm those details with your chosen platform before placing a trade.

Start with LMAT's quarterly and annual filings, where you can review revenue growth, gross and operating margins, net income, and cash flow. Comparing these figures across several periods helps show whether trends are improving or slowing. Balance-sheet items such as cash, debt, and inventory also matter for a medical device company. Earnings releases and investor presentations provide management commentary. Together, these sources give a factual basis for assessing LMAT's financial performance over time.

LMAT faces risks common to medical device companies, including regulatory approvals, product recalls, competition, and reliance on hospital purchasing cycles. Reimbursement changes and pricing pressure can affect demand. International sales expose LMAT to currency movements and regional economic conditions. Supply chain disruptions or manufacturing issues could also impact results. Stock-specific risks include valuation sensitivity and share price volatility. Review LMAT's risk factor disclosures in its latest filings for a complete, company-specific list.